Bortezomib, identified by the Chemical Abstracts Service (CAS) number 179324-69-7, stands as a pivotal Active Pharmaceutical Ingredient (API) in modern oncology. This potent compound is classified as a proteasome inhibitor, a mechanism that has revolutionized the treatment landscape for certain types of cancer.

The primary function of Bortezomib is to block the activity of proteasomes, cellular complexes that break down proteins. By inhibiting this process, the API disrupts essential cellular functions, particularly in cancer cells, leading to their apoptosis (programmed cell death). This targeted approach makes Bortezomib highly effective against malignancies where proteasome activity is crucial for survival and proliferation.

Clinically, Bortezomib (CAS 179324-69-7) has demonstrated significant efficacy in treating specific hematologic cancers. Its established uses include the management of multiple myeloma and mantle cell lymphoma. These applications highlight its importance as a cornerstone therapy, often used in combination with other agents to enhance patient outcomes.

As a pharmaceutical raw material, Bortezomib presents as a white to off-white powder. Ensuring its quality and purity is paramount for the safety and effectiveness of the final drug product. High-grade Bortezomib API typically boasts a purity level exceeding 99%, meeting stringent medicine grade standards such as those aligned with GMP, FDA, and ISO guidelines. Comprehensive quality control involves rigorous testing for identity, solubility, water content, sulfated ash, heavy metals, residual solvents, related substances, and microbial contamination. Batches are carefully analyzed to confirm adherence to predefined specifications, ensuring consistency and reliability.

The reliable sourcing of high-quality Bortezomib API is critical for pharmaceutical manufacturers globally. Availability, purity, and documentation are key considerations when selecting a supplier. Reputable providers adhere to strict manufacturing processes and provide detailed certificates of analysis. Bortezomib is typically packaged in protective materials like cardboard drums or cartons and requires storage in tight, light-resistant containers in a cool environment to maintain its stability and integrity over time.

For pharmaceutical companies engaged in developing or manufacturing oncology treatments, finding a dependable Bortezomib manufacturer is essential. Exploring options from various sources allows for assessment of quality, supply chain reliability, and competitive pricing. Whether you are looking to buy Bortezomib for research and development or require bulk quantities for commercial production, understanding the market dynamics and supplier capabilities is crucial. Information regarding the Bortezomib price and minimum order quantities is typically available upon inquiry from potential suppliers. Making a strategic Bortezomib purchase requires due diligence to ensure the material meets all necessary regulatory and quality specifications for its intended use in life-saving medications. Partnering with an experienced Bortezomib supplier ensures access to consistent quality and technical support.